A new coronavirus known as SARS-CoV-2 is rapidly spreading over the world, posing a significant public health hazard. In response to this worldwide health crisis, several preventive initiatives have been launched; among these, vaccine discovery is on the cutting edge. A vaccine against SARS-CoV-2 has been developed using several advanced designs, and forty four candidates have already begun clinical testing. At the moment, it's unclear whether ones will meet the efficiency and safety criteria, and several vaccines are awaiting urgent clearance in the United States and Other countries. The advantages and disadvantages of several vaccination technologies, as well as the safety and effectiveness of vaccines in their early stages, were examined in this research. Following the development of a vaccine, the acquisition, deployment, and uptake of the vaccine will be the next challenges. The current manuscript delves into these issues in depth and offers solutions to a wide range of translational issues. SARS-epidemiology CoV-2's indicates that the virion will continue to be a hazard to everyone as longer as a few people are infected. We require vaccines that are both inexpensive and available in sufficient quantities to be used in all parts of the globe.